At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRMD CorMedix Inc.
Market Closed 05-08 16:00:00 EDT
7.92
+0.00
0.00%
盘后7.92
+0.000.00%
19:09 EDT
High8.15Low7.82Vol858.92K
Open8.03D1 Closing7.92Amplitude4.17%
Mkt Cap624.01MTradable Cap583.66MTotal Shares78.79M
T/O6.81MT/O Rate1.17%Tradable Shares73.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CorMedix to report Q1 results, host corporate update call
Reuters  ·  05-05
CorMedix to report Q1 results, host corporate update call
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
THOMSON REUTERS  ·  05-05
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
Citizens healthcare analysts hold an analyst/industry conference call
TIPRANKS  ·  04-29
Citizens healthcare analysts hold an analyst/industry conference call
CorMedix Is Maintained at Outperform by Leerink Partners
Dow Jones  ·  04-28
CorMedix Is Maintained at Outperform by Leerink Partners
RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  04-28
RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Cormedix (CRMD) and Relay Therapeutics (RLAY)
TIPRANKS  ·  04-28
Analysts Offer Insights on Healthcare Companies: Cormedix (CRMD) and Relay Therapeutics (RLAY)
CorMedix Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  04-27
CorMedix Is Maintained at Buy by D. Boral Capital
BRIEF-Cormedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial
Reuters  ·  04-27
BRIEF-Cormedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial
CorMedix says Phase III ReSPECT trial meets primary endpoint for REZZAYO prophylaxis
Reuters  ·  04-27
CorMedix says Phase III ReSPECT trial meets primary endpoint for REZZAYO prophylaxis
CorMedix Inc - Companies Anticipate Pre-Nda Meeting With FDA, Target Snda Submission in 2H26
THOMSON REUTERS  ·  04-27
CorMedix Inc - Companies Anticipate Pre-Nda Meeting With FDA, Target Snda Submission in 2H26
CorMedix Inc - Study Shows Favorable Benefit for Toxicity Related Discontinuations and Drug-Drug Interactions
THOMSON REUTERS  ·  04-27
CorMedix Inc - Study Shows Favorable Benefit for Toxicity Related Discontinuations and Drug-Drug Interactions
CorMedix Inc - Rezafungin Well Tolerated With Safety Profile Comparable to Standard Regimens
THOMSON REUTERS  ·  04-27
CorMedix Inc - Rezafungin Well Tolerated With Safety Profile Comparable to Standard Regimens
CorMedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial Assessing Rezzayo® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
THOMSON REUTERS  ·  04-27
CorMedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial Assessing Rezzayo® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
CorMedix Inc - Respect Study Meets Primary Endpoint for Fungal-Free Survival at Day 90
THOMSON REUTERS  ·  04-27
CorMedix Inc - Respect Study Meets Primary Endpoint for Fungal-Free Survival at Day 90
RBC Capital Sticks to Its Buy Rating for Cormedix (CRMD)
TIPRANKS  ·  04-09
RBC Capital Sticks to Its Buy Rating for Cormedix (CRMD)
CorMedix to join Needham Virtual Healthcare Conference fireside chat and investor meetings
Reuters  ·  04-07
CorMedix to join Needham Virtual Healthcare Conference fireside chat and investor meetings
CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M
TIPRANKS  ·  03-07
CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M
CorMedix price target lowered to $13 from $15 at Leerink
TIPRANKS  ·  03-07
CorMedix price target lowered to $13 from $15 at Leerink
Cormedix (CRMD) Receives a Buy from RBC Capital
TIPRANKS  ·  03-06
Cormedix (CRMD) Receives a Buy from RBC Capital
CorMedix Is Maintained at Buy by Needham
Dow Jones  ·  03-06
CorMedix Is Maintained at Buy by Needham

Introduction

Company Name.
CorMedix Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Issue price:
--